Medical Device

- Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash.

Novasep's viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium , Novasep's viral vector business offers more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million ).

"Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde , executive vice president of Thermo Fisher . "The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America . In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.  The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe ."

Michel Spagnol , president and chief executive officer of Novasep said, " Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher . Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients."

The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit .

About Novasep

Novasep is a global provider of cost effective and sustainable manufacturing solutions for life sciences molecules. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing and complex active molecule services for pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

Safe Harbor Statement

The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our website under the heading "SEC Filings."  While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific)

Media Contact Information:
Ron O'Brien
Phone: +1 781-622-1242

Investor Contact Information:
Ken Apicerno
Phone: +1 781-622-1294

For Novasep
Agnes Catineau
Phone: +33 7 78 50 95 46

Cision View original content to download multimedia:

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

Danaher Releases 2022 Sustainability Report and Announces New Greenhouse Gas Emissions Reduction Target

- Danaher Corporation (NYSE: DHR) (the "Company"), the global science and technology innovator, today published its 2022 Sustainability Report which highlights the progress of the Company's sustainability program. Danaher also announced it has set a new goal to reduce its absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 50.4% by 2032, compared to a baseline year of 2021—aligning to the prevailing climate science goal of limiting global warming to 1.5 degrees Celsius above pre-industrial levels.

"Every day across Danaher, we work to positively impact the world around us in meaningful ways," said Rainer Blair , President and Chief Executive Officer. "We feel a strong sense of responsibility to exceed the expectations of our stakeholders across the many facets of sustainability, and within this challenge we see tremendous opportunity to help all our stakeholders Realize Life's Potential . Thanks to the driving force of the Danaher Business System, we have made notable progress across our sustainability endeavors this year and are excited to set our future ambitions even higher."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Seasonal Affective Disorder Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022

CMS Issues New Clarification on ICD-10 Coding for SAD

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") is continuing its commitment to improving lives with the announcement of modifications within the Tabular Index, specifically for the prevention and treatment of SAD from the Centers for Medicare & Medicaid Services (CMS). Now, all appropriate codes have been combined into a bundle for SAD which allows healthcare professionals to further clarify a diagnosis in an easy-to-understand index tab and send all diagnoses for SAD to one simple code: F33. This achievement helps further define SAD as a recognizable condition that may be diagnosed and appropriately treated.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 26, 2022

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2022 before the market opens on Wednesday, October 26, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 406803. You may also listen to the call live on the "Investors" section of our website, . The earnings press release and related information can be found in that section of our website under "Earnings Results." A replay of the call will be available under "News and Events" through Friday, November 11, 2022.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31 st Annual Global Healthcare Conference on Thursday, November 10 th , 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:50 p.m. (Eastern Time).

This audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less


Centers for Medicare & Medicaid Services (CMS) Launch of New Code Coincides with Liver Awareness Month, a Time to Make Liver Health a National Health Care Priority

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain. According to recent data, hospitalized patients readmitted within 30 days with HE have a 20% 1-year mortality rate. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Inc. ("ALRT") (OTCQB: ALRT), the diabetes management company, is pleased to announce an update with respect to its migration to Singapore. Further to its Form 8-K filed May 20, 2022, and press release issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. ("ALRT Singapore"), has been declared effective by the Securities and Exchange Commission (the "SEC"). ALRT anticipates mailing the corresponding prospectus and information statement to its stockholders on or around October 4, 2022. ALRT expects to consummate the previously announced reincorporation merger in which ALRT will become a wholly owned subsidiary of ALRT Singapore as soon as practicable following the required 20-day waiting period subsequent to mailing of the prospectus and information statement, subject to the satisfaction of customary closing conditions, including certain regulatory approvals from FINRA, the OTC Markets Group, ACRA (Singapore), and the Secretaries of State of Nevada and Delaware.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News